BioCentury
ARTICLE | Company News

Acumen Pharmaceuticals, Merck deal

December 4, 2006 8:00 AM UTC

The companies amended a 2004 agreement, giving MRK exclusive R&D rights to diagnostic products directed at amyloid-derived diffusible ligands (ADDLs). All other rights in the original agreement remain...